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The only real failure is the failure to try, and the measure of 
success is how we cope with disappointment, as we must… We 
get up in the morning, we do our best, nothing else matters. 
 
---The Best Exotic Marigold Hotel 
 
  
ABSTRACT 
Cholesterol carries multiple biological functions in the body, and imbalanced 
cholesterol metabolism leads to atherosclerosis and cardiovascular diseases. The 
present thesis aims to extend the knowledge of cholesterol metabolic regulation 
mediated by nuclear receptor LXRs and bile acids, two major players in the 
homeostasis of body cholesterol. 
 
In the first paper, we aim to understand how liver X receptor (LXR) regulates 
cholesterol metabolism in the intestine, in particular to compare the effects of the two 
isoforms, LXRα and LXRβ on dietary cholesterol absorption and serum lipoprotein 
profiles. We find that selective activation of LXRβ enhances dietary cholesterol 
absorption in mice, which is accompanied by increased apoB lipoprotein cholesterol in 
the circulation. We also find that LXRα and LXRβ compensate for each other in the 
transcriptional regulation of intestinal Abcg5, Abca1 and Npc1l1. Furthermore, the 
hepatic enzymes Cyp7a1 and Cyp8b1 are differently modulated upon systemic LXR 
isoform activation. Given the contribution of the hydrophobic bile acid profile in the 
intestine, these changes together with the net differences in biliary cholesterol output 
may partially explain the isoform mediated changes in cholesterol absorption. Our 
findings reinforce the non-redundant function of LXRα and LXRβ, and suggest that 
selective activation of LXRβ as anti-atherogenic therapy may lead to undesired 
metabolic adverse effects. 
 
Bile acid synthesis represents the crucial elimination pathway for excess cholesterol. 
The negative feedback regulation by end-product hydrophobic bile acids has been well 
established, involving the activation of nuclear receptor FXR, and a subsequent 
upregulation of SHP and Fgf15 for the suppression of bile acid synthesis in mice 
(Fgf19 as human counterpart). However, the role of hydrophilic bile acids in such 
context has largely been ignored. By using a cholic acid (CA) deficient mouse model 
and different bile acid-modulating regimes, we define MCAs as FXR antagonistic bile 
acids, which counteract the FXR activation by hydrophobic bile acids. By modulating 
the enterohepatic circulation of bile acids, the positive feedback mechanism regulates 
bile acid homeostasis without employing the hormonal effect of Fgf15, although such 
an effect is likely to exist. This finding is of fundamental importance for the 
understating of bile acid metabolism in both humans and mice, as the Fgf15/19 
negative feedback mechanism is believed to operate in both species. 
 
Paper III explores the therapeutic potential of CA depletion on systemic cholesterol 
overloading by using second generation antisense oligonucleotides (ASOs). Several 
ASOs targeting Cyp8b1, the enzyme responsible for CA production, have been used in 
the study. In mice, we observe a significant reduction of the CA fraction in the biliary 
bile acid profile under ASO treatment. This reduction is accompanied by resistance to 
liver cholesterol accumulation and an athero-protective lipoprotein profile upon 
cholesterol overloading. The data suggest the feasibility of using second generation 
ASOs as therapeutic target for cholesterol homeostasis, although a careful systematic 
study is needed to address the clinical aspect in human subjects. 
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1 INTRODUCTION 
 
1.1 CHOLESTEROL METABOLISM 
Cholesterol is an essential structural component of the mammal cell responsible for the 
establishment of membrane permeability and fluidity. In addition, cholesterol also 
serves as a precursor for the biosynthesis of steroid hormones and bile acids (Figure 1). 
The whole body cholesterol homeostasis is balanced by the de novo synthesis, dietary 
intake and excess cholesterol excretion. According to the literature, dietary cholesterol 
intake constitutes around 1/4 of the daily total body cholesterol turnover, while the rest 
is contributed by de novo synthesis [1]. Almost all cell types have the ability to 
synthesize cholesterol, which is a long energy demanding process. These steps are 
precisely regulated by the body in relation to demand, as a high level of cholesterol in 
the circulation is associated with the progression of atherosclerosis and other 
cardiovascular diseases. 
 
 
Figure 1. Chemical structure of cholesterol 
 
 
1.1.1 De novo cholesterol synthesis  
The synthesis of cholesterol starts from acetyl-CoA, a substance derived from the 
oxidative reaction of fatty acids or pyruvate. Several enzymes are involved in 
cholesterol synthesis, of which the rate-limiting enzyme is 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCoAR). It converts 3-hydroxy-3-methylglutaryl 
Coenzyme A (HMGCoA) to mevalonic acid. This is an irreversible step in the 
cholesterol synthesis process, and also represents the target site of action for drug 
design. Commercially available drug statins inhibit HMGCoAR for the treatment of 
atherosclerosis [2]. 
 
Due to its crucial nature in the course of cholesterol synthesis, HMGCoAR is subjected 
to strict regulations under multiple stages. The transcriptional regulation of the enzyme 
involves sterol regulatory element binding protein (SREBP), which can be translocated 
to the nucleus when the cellular cholesterol level goes down, and therefore upregulates 
the HMGCoAR transcriptional level [3, 4]. In addition, the enzyme is also subjected to 
short term posttranslational regulation such as biodegradation or phosphorylation. 
Studies show that rising levels of sterols increase the susceptibility of HMGCoAR to 
ER-associated degradation and proteolysis [5, 6] 
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1.1.2 Intestinal cholesterol absorption 
The cholesterol absorption is important for the whole body cholesterol maintenance. 
Cholesterol entering the gut originates from various sources, e.g. the bile, diet, trans-
intestinal cholesterol efflux and cell membrane debris. All food containing animal fat 
contains cholesterol at various levels, as animal fat is a mixture of predominant 
triglycerides with little phospholipids and cholesterol. Due to its hydrophobic nature, 
cholesterol forms micelles with triglycerides, plant sterols, bile acids, free fatty acids, 
and other lipids when entering the gut [7, 8]. Cholesterol with biliary origin is mostly 
unesterified, which entails more efficient absorption by the intestine.  
 
The crucial step of cholesterol uptake takes places in the proximal small intestine, in 
particular the enterocytes, which express several transporters to facility the cholesterol 
absorption. It has been demonstrated that Neimann-Pick C1 Like 1 (NPC1L1) is 
important for the uptake of cholesterol and plant sterols at the brush border membranes 
of the enterocytes [9-11]. After entering the enterocytes, most of the free cholesterol is 
then esterified by acyl coenzyme A: cholesterol acyltransferase 2 (ACAT2), and 
assembled into chylomicrons with a large amount of triglycerides [12, 13]. The 
chylomicrons are then transported to the liver and peripheral tissues via blood 
circulation for energy supply or storage. The free cholesterol in the enterocyte can also 
be assembled into high-density lipoprotein (HDL), a process which requires ATP-
binding cassette transporter ABCA1 located on the basolaterol side of the enterocyte. A 
study using intestinal specific Abca1 knockout mice has demonstrated that the small 
intestine contributes up to 30% of the total plasma HDL [14]. Unlike free cholesterol, 
most of the plant sterols are exported back to the intestinal lumen via the apical co-
transpoter ABCG5/G8. Mutations in either gene cause sitosterolemia, a rare recessive 
disease with high levels of neutral sterol in the plasma and the tissue [15]. In contrast, 
overexpression of ABCG5/G8 by different approaches significantly reduces the 
cholesterol absorption in mice [16]. Reducing cholesterol absorption is regarded as a 
promising approach to treat hypercholesterolemia. The drug ezitimibe, a synthetic 
NPC1L1 inhibitor, has been approved for such indications.  
 
 
1.1.3 Lipoproteins and apopipoproteins in the blood 
The common structure of lipoprotein particles represents a biochemical assembly with 
a hydrophilic surface and lipophilic core. Non-polar molecules such as the 
triglycerides, esterified-cholesterol and other hydrophobic molecules are packed inside 
the particle, while the polar ends of apolipoproteins, phospholipids and free cholesterol 
are located on the surface. Each lipoprotein particle has one or several apolipoproteins 
embedded on the surface, acting as ‘’hallmarks’’ for the recognition of particles by 
relevant lipoprotein receptors during metabolism. 
 
Lipoproteins can be classified by their hydrate density or electrophoretic mobility. Due 
to the fact that the density of the non-polar core is usually low while the polar surface 
high, the size of the lipoprotein particles is therefore inversely correlated to the density. 
Chylomicrons and very low-density lipoprotein (VLDL) represent the two largest 
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lipoprotein particles in the blood, followed by smaller particles such as the intermediate 
density lipoproteins (IDL), the low density lipoproteins (LDL) and the HDL.  
 
The presence of apolipoproteins is essential in the blood due to their crucial roles in 
lipid transportation and atherogenic processes. A large number of apolipoproteins has 
been identified and carefully studied [17, 18]. The subtypes of apolipoproteins contain 
apoAs, Bs, Cs, D, E, etc. From the evolutionary point of view [19], the smaller 
proteins, i.e. apoAs, apoCs and apoE share similar sequences in the coding regions and 
their genomic structures. ApoB, on the other hand, differs from the other 
apolipoproteins in the genomic sequences by having 29 exons including two extremely 
long ones. It exists in two different forms, the apoB-100 and apoB-48, which is a 
truncated protein that appears only in the small intestine. It represents 48% of the amino 
acid sequences in apoB-100 due to the introduction of a stop codon in the mRNA 
sequences. Therefore lipoproteins containing apoB-48 can be identified as of intestinal 
origin in humans. According to the established theory, the major 3D structure of apoB 
is mainly a beta-sheet, which allows the irreversible association of the apolipoprotein to 
the lipid droplet. In contrast, the other apolipoproteins mainly have alpha-helices as the 
3D structure, which are then associated to the lipid droplets reversibly.  Accordingly, 
apoBs are mostly found in the LDL or IDL, whereas HDL mainly contains apoAs and 
apoE.  
 
 
1.1.4 Lipoprotein metabolism 
The exogenous pathway 
The exogenous pathway, specifically the metabolism of chylomicrons, represents the 
metabolism of cholesterol, triglycerides and free fatty acids, which enter the gut via the 
bile or the diet. After each meal, micelles (a mixture of cholesterol, triglycerides, 
phospholipids and bile acids) are formed and are taken up by transporters located on the 
enterocytes. Within the enterocyte, free cholesterol forms cholesteryl esters with fatty 
acids, and is subsequently packed into nascent chylomicrons with apolipoproteins 
(mainly apoB-48, apoC-I, apoC-III), phospholipids and triglycerides to be secreted into 
the lymph. In the circulation, chylomicrons acquire apoC-II and apoE from HDL and 
become mature. The acquisition of apoC-II enables chylomicrons to activate 
lipoprotein lipase, which is located on the luminal side of endothelial cells, and 
catalyzes the hydrolysis of triglycerides into free fatty acids and monoacylglycerol. 
These products are taken up by adipose tissue and muscle cells for energy supply or 
storage. The leftover part of the chylomicrons, namely chylomicron remnants, remains 
in the circulation until they interact with the chylomicron remnant receptor in the liver 
via apoE, and taken up by the hepatocytes for the further degradation by the lysosome. 
 
The endogenous pathway 
The endogenous pathway starts with the assembly of the nascent VLDL in the liver, 
which contains esterified cholesterol, triglycerides, phospholipids and apoB-100. The 
nascent VLDL is released from the hepatocyte into the circulation, where it acquires 
apoC-II and apoE from the HDL, eventually becoming mature. Similar to 
chylomicrons, VLDL particles also undergo the hydrolysis of lipoprotein lipase via 
apoC-II, and release monoacylglycerol and free fatty acids for the energy storage by 
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peripheral tissues. After the hydrolysis, the VLDL remnants (also called intermediate-
density lipoprotein, IDL) are further hydrolyzed by the hepatic lipase and become LDL. 
The LDL particle is enriched with cholesterol and contains only apoB-100 as 
apolipoprotein. In humans, it represents the major cholesterol transportation particle. It 
circulates in the blood stream and can be recognized by the LDL receptor (LDLr) 
before entering the cell by endocytosis. Most of the LDL particles are then degraded by 
the lysosome and lipid components are further hydrolyzed. As lipoproteins accumulate 
in the intima of the arterial vessels, they can be oxidized by the oxygen free radicals 
generated by either macrophages or endothelial cells. These oxidized LDL particles, 
however, can also be taken up by the macrophages which later become foam cells and 
form the fatty streaks of the plaque inside the intima of the arteries. A high level of 
LDL in the circulation is a known risk for atherosclerosis. As every LDL particle 
contains only one molecule of apoB-100, the level of apoB-100 in the circulation is a 
helpful marker for the evaluation of the LDL particles and therefore useful for 
predicting the development of atherosclerosis. 
 
Reverse cholesterol transportation 
The reverse cholesterol transportation (RCT) represents the multi-step process of 
cholesterol net movement from the peripheral tissue to the liver for the elimination via 
bile. It was first described by Glomset in 1973 [20], and was regarded as a protective 
event against cardiovascular disease by the synthesis and metabolism of HDL. The 
procedures of RCT include cellular cholesterol efflux, HDL remodeling and HDL 
transportation from the peripheral tissue to the liver. HDL contains mainly apoA-I as 
apolipoprotein, with apoA-II present in some HDL particles, although its role is less 
well defined [21, 22]. Intercellular free cholesterol is effluxed by the ABCA1 and 
interacts with apoA-I, which facilities the esterification of cholesterol by 
lecithin:cholesterol acyltransferase (LCAT). Nascent HDL matures as the amount of 
cholesteryl esters accumulate via remodeling in the circulation. These mature HDL 
particles are then interacting with hepatocytes through its receptor, the scavenger 
receptor class B type I (SRBI). SRBI thereafter mediates non-endocytotic cholesterol 
transport into the hepatocyte.  
 
 
1.2 BILE ACID METABOLISM 
Bile acids are important cholesterol derivatives during the metabolic process. The 
synthesis and excretion of bile acids represents a major path to eliminate excess 
cholesterol in the body. In most of the early studies, bile acids have been recognized 
merely as detergent facilitating lipid absorption in the gut. Recent studies revealed 
crucial functions of bile acids as signaling molecules and their important roles in 
governing lipid metabolism, energy expenditure, glucose metabolism, carcinogenic 
balance, etc.  
 
 
1.2.1 Synthesis of primary bile acids 
About 500 mg of cholesterol are converted daily into bile acids in the adult human liver 
[23]. The synthesis takes place exclusively in the liver. The intermediate products of the 
synthesis are named as primary bile acids, with various chemical structures indicating 
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the different biological functions. In humans, the most predominant primary bile acids 
are cholic acid (CA) and chenodeoxycholic acid (CDCA) (Figure 2), whereas in mice 
and rats, the primary bile acids mainly consist of CA and muricholic acids (MCA).  
 
(A)                                                (B)    
 
 
 
Figure 2. Chemical structures of (A) cholic acid and (B) chenodeoxycholic acid. 
 
Two major pathways have been identified for the bile acid synthesis, namely the classic 
pathway (or the neutral pathway) and the alternative pathway (or the acidic pathway). 
The crucial steps in the classic pathway involve the participation of several enzymes, of 
which the rate-limiting one is cholesterol 7α-hydroxylase (CYP7A1). This enzyme 
belongs to the cytochrome P-450 super family, is expressed exclusively in the liver, and 
is subjected to strict regulation by a number of nuclear receptors and other signaling 
pathways.  
 
Cyp7a1-deficient mice reveal a complex phenotype and high mortality rate in their 
early life stage, indicating the crucial function of this enzyme in the murine metabolic 
system [24]. However, the above observation seems to vary according to experimental 
condition and genetic background, as another study using mice with disrupted Cyp7a1 
observed a much lower mortality rate and milder clinical phenotype [25]. In addition, 
an elevated level of serum cholesterol was detected in these mice. These observations, 
however, seem to be more representative to the human Cyp7a1 deficient condition. A 
common variation of the human CYP7A1 gene is the single nucleotide polymorphism 
(SNP) in the promoter region of the gene, resulting in an A/C transversion and 
subsequently higher level of LDL-cholesterol [26, 27].  
 
In this way, cholesterol can either be converted to CA or CDCA before entering the 
enterohepatic circulation. The P-450 cytochrome enzyme sterol 12α-hydroxylase 
(CYP8B1) is crucial for the synthesis of CA. It is exclusively expressed in the liver and 
regulated by the sterol regulatory element binding proteins (SREBPs) [28, 29]. In a 
mouse model with genetic disruption of Cyp8b1, the CA synthesis was completely 
abolished, which resulted in a dramatic increase of MCA and CDCA [30]. This change 
resulted in reduced dietary cholesterol absorption, increased liver bile acid synthesis, an 
expanded bile acid pool, and increased resistance to atherosclerotic formation when 
cross-bred with apoE knockout mice [31-33]. In humans, no individual with CYP8B1 
deficiency has been described and a polymorphism found in the coding region of the 
gene does not seem to correlate with the difference in the ratio between CA and CDCA 
[34]. A report described a change of the CA/CDCA ratio in human bile in cystic 
fibrosis patients, but no correlation was found between the ratio and the disease onset  
[35]. The alternative (acidic) pathway also plays an important role for the bile acid 
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synthesis. It contributes to about 25% of the bile acids in rodents, but less in humans 
[23]. The key enzyme of this step represents the sterol 27-hydroxylase (CYP27A1). 
Mice with disrupted Cyp27a1 display a reduced total bile acid pool, and a 
predominance of CA in the total bile acid composition [36]. Human CYP27A1 
deficiency is the cause of cerebrotendinous xanthomatosis (CTX), which is 
characterized by dementia, ataxia, cataracts and xanthomas in the central nerve system 
and peripheral tendons [37].  
 
 
1.2.2 Enterohepatic circulation and secondary bile acid synthesis 
The enterohepatic circulation is important in maintaining a constant bile acid pool size, 
which is measured as 4 mg in mice and 2 to 4 g in humans [38-40]. These bile acids 
circulate several rounds in each meal, facilitating the absorption of lipids in the food 
while act as signaling factors for the metabolism of glucose and energy [41-44].  
 
The hepatocytes have the ability to transport bile acids efficiently from the portal blood 
into the bile, a step that is essential for the bile acid enterohepatic circulation. The 
transportation process is driven by the Na+-taurocholate co-transporting polypeptide 
(NTCP). This membrane glycoprotein is the founding protein of the SLC10 
superfamily for solute carrier proteins, which consists of two bile acid carriers, 
SLC10A1 (NTCP) and SLC10A2 (ASBT) [45]. The high expression level of NTCP on 
the sinusoidal membrane of the hepatocytes enables the transporter to extract bile acids 
efficiently from the portal blood, with the highest affinity to the conjugated bile acids 
and weaker affinity to unconjugated or sulfated bile acids [46-48]. On the canaliculi 
side of the hepatocytes, the bile salt export pump (BSEP) is located. This ABC 
transporter acts as canalicular bile acid exporter and effluxes bile acids into the bile. 
After each meal, the contraction of the gallbladder empties the bile from the biliary 
tract into the gut where the bile acids meet with the apical sodium bile transporter 
(ASBT) in the distal ileum. There, about 95% of the BAs are reabsorbed, a step that is 
crucial for the maintaining of the total BA pool size [49, 50]. These bile acids are then 
taken into the enterocytes and exported by the organic solute transporters (OSTs), 
which form a dimer between the subtypes OSTα and OSTβ, into the blood [51, 52], 
transported back to the liver via the portal blood, and thereby complete a round of 
enterohepatic circulation. 
 
Not all the BAs are reabsorbed in the distal ileum. Less than 5% of the leftover BAs 
continue to the large intestine, where they are converted by the bacteria into secondary 
BAs. In humans and rodents, the secondary BAs formed by the colon bacteria are 
consisted of deoxycholic acid (DCA), lithocholic acid (LCA) and a small amount of 
ursodeoxycholic acid (UDCA). The percentage of DCA is much higher in humans 
(about 25% of total bile acid pool) as compared to rodents, whose DCA fraction is less 
than 1% due to the re-hydroxylation ability in their liver. Secondary BAs are more 
lipophilic and therefore exhibit higher cellular toxicity than the primary BAs.  
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1.3 REGULATION OF CHOLESTEROL METABOLISM  
 
Since the discovery of nuclear receptors, significant progress has been made in the 
ligand identification and physiological function dissection. Among them are the liver X 
receptor (LXR) and farnesoid X receptor (FXR), whose natural ligands were previously 
unknown. It is now clear that the ligands for LXRs are mainly cholesterol derivatives, 
while bile acids account for the ligands of FXR. These two nuclear receptors play 
crucial roles in the regulation of genes related to lipid homeostasis. 
 
 
1.3.1 Nuclear receptors 
Nuclear receptors are a group of proteins located within the cell nucleus, of which most 
can bind directly to DNA. A common character they share is the ability to bind ligands 
such as steroids and other lipid molecules. Upon the ligand binding, nuclear receptors 
commence conformational changes that result in the transcriptional signaling change, 
leading to the up or down-regulation of certain target genes. Recent studies reveal that 
transcriptional regulation by nuclear receptors also requires the participation of co-
activators, which are recruited after the ligand binding procedure [53, 54]. The common 
structure of the nuclear receptors consists of an N-terminal domain, regions of DNA 
binding, hinging, ligand binding, and a C-terminal domain (Figure 3) [55, 56].  
 
 
 
 
Figure 3. Schematic diagram of a typical nuclear receptor with its functional domains. 
 
 
1.3.2 LXRs, cholesterol homeostasis and synthetic LXR agonists 
LXRs are transcriptional factors which belong to the nuclear receptor superfamily. It 
was first identified as orphan receptor, of which the natural ligand was unknown. LXR 
forms a heterodimer with the retinoid X receptor (RXR) and therefore can also be 
activated by RXR agonists. Upon ligand binding, LXR experiences conformational 
changes resulting in the release of co-suppressors and recruiting of co-activators. 
Thereafter, the transcriptional regulation of the target genes is initiated. Natural ligands 
for LXRs includes cholesterol metabolites, oxysterols such as 24(S),25-
epoxycholesterol, 24(S)-hydroxycholesterol, and 27-hydroxycholesterol [57-59]. These 
molecules are believed to act as endogenous LXR activators in tissues like liver, 
intestine and macrophages. LXR has two subtypes, LXRα (NR1H3) and LXRβ 
(NR1H2), which share approximately 77% identity in DNA and ligand-binding 
domains. These two subtypes however have different expression frequencies in various 
tissues [60, 61]. LXRα is expressed in lipid-metabolic tissues such as the liver, 
intestine, macrophage, etc; while LXRβ is more ubiquitously expressed and governs a 
multitude of metabolic functions.  
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Genetically modified animal models have been created to study the impact of LXRs in 
relation to the lipid metabolites. In the macrophage, LXRα regulates cholesterol efflux 
transporters upon activation. Genes such as ABCA1, ABCG1, apoC and apoE were 
significantly upregulated under LXR stimulation, and therefore facilitate the 
intracellular sterol efflux for the return as HDL to the liver [62]. Activation of LXRs 
also affects the intestinal cholesterol absorption, although the exact mechanism has not 
been completely clear. When LXRα knockout mice were cross-bred with apoE 
knockout mice, the new strain showed an attractive phenotype for the study of 
atherosclerosis, as the number of atherosclerotic lesions was significantly decreased in 
the double knockout mice [31]. A novel insight on how LXRs regulate lipid 
homeostasis was added when a new LXR target gene was identified, namely the 
inducible degrader of LDL receptor (IDOL, also known as MYLIP) [63]. The E3 
ubiquitin ligase functions as a degrader for the LDL particles and LDL receptor, 
thereby affecting the LDL levels in the blood. The identification of IDOL reinforces the 
crucial role of LXR in preserving cellular lipid homeostasis under cholesterol 
overloading conditions.  
 
A large number of synthetic LXR agonists has been created by the pharmaceutical 
industry aiming to treat atherosclerosis and other indications. The first generation of the 
LXR pan-agonist, TO-901317 and GW3965 have been synthesized by Amgen 
(Tularik) and GlaxoSmithKline, respectively, and widely used in preclinical studies. 
The beneficial effects of these two agonists are shown in many animal models of 
different indications ranging from cardiovascular diseases, neuro-degenerative diseases, 
inflammatory diseases and other metabolic disorders. However, such beneficial effects 
are clearly counteracted by the significant adverse effects associated with the products, 
as mice treated with first generation LXR agonists developed hypertriglyceridemia 
[64], a known risk factor for cardiovascular disease. This phenotype has largely been 
attributed to the up-regulation of sterol regulatory element binding protein 1c 
(SREBP1c), a direct target gene of LXR. The activation of SREBP1c leads to massive 
induction of its downstream genes related to fatty acid synthesis, including fatty acid 
synthase (FAS), acetyl-CoA carboxylase, and stearoyl CoA desaturase-1 (SCD-1) [65]. 
Later on, Wyeth developed LXR-623, another LXR agonist which preserved the 
beneficial effects of its first generation, but without the elevation of hepatic lipogenesis. 
However, the clinical trial for LXR-623 was forced to be discontinued due to the severe 
neurological side effects during the clinical trial [66].  
 
 
1.3.3 FXR and bile acid metabolism  
The original name of FXR (NR1H4) comes from the observation that farnesol acts as 
the ligand for this nuclear receptor [67]. In the subsequent studies, it has become more 
and more clear that bile acids are the actual natural ligands for FXR [68, 69]. FXR is 
mainly expressed in the liver, intestine, kidney and adrenal glands, whereas low levels 
of expression are also discovered in adipose tissue and heart. Similar to LXRs, FXR 
also forms a heterodimer with RXR and responds to RXR agonists. The transcriptional 
regulation of the target genes starts when bile acids bind to FXR. In addition, FXR can 
also exert indirect regulation of certain genes via the induction of small heterodimer 
partner (SHP). It is important to dissect the physiological role of pure FXR activation, 
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as bile acids also act as ligands for other nuclear receptors such as pregnane X receptor 
(PXR), constitutive androstane receptor (CAR), vitamin D receptor and TGR5. For this 
reason, it is important to use FXR-deficient mice in order to draw conclusions for FXR-
mediated metabolic effects observed by exogenous bile acid activation. 
 
High levels of bile acids are cytotoxic; therefore it is crucial to maintain the proper bile 
acid levels in the body. To achieve this task, FXR regulates the flux of bile acid in 
various feedback or feedforward loops, covering the bile acid synthesis, uptake, 
transportation and reabsorption. FXR knockout mice also show several severe 
metabolic phenotypes, which adds to the evidences that FXR is crucial for bile acid 
flux and overall metabolic homeostasis. The regulation of bile acid synthesis by FXR is 
mainly through the FXR-SHP activation, which then inhibits the liver receptor 
homolog-1 (LRH-1), LXR and hepatocyte nuclear factor 4α (HNF4α), factors all 
necessary for the preservation of CYP7A1 expression [70-72]. In addition, it has been 
claimed that bile acid-FXR signaling also induces the fibroblast growth factor 19 
(FGF19, Fgf15 as homolog in rodents), which is synthesized in the distal intestine and 
exerts hormonal effects in the liver by repressing CYP7A1 expression. Although the 
hormonal function of Fgf15 has been predicted long ago, it is not until recently that the 
protein has been detected in the blood for the first time in mice [73]. This could either 
be due to instability or the fast degradation rate of the protein, which raises the question 
of its real physiological function in rodents. Nevertheless, FXR activation leads to 
suppression of CYP7A1 in the liver, resulting in a feedback regulatory effect of bile 
acid synthesis. In addition to the bile acid synthesis, FXR modulates bile acid flux by 
transcriptional regulation of ASBT and OSTα/β [74]. The FXR-mediated regulation of 
bile acid synthesis implied the crucial role of FXR as lipid regulator, as bile acid 
synthesis represents an important way for cholesterol elimination.  
 
 
1.3.4 Bile acids as ligands for G-protein coupled receptors (TGR5) 
In addition to their lipid solubility function, bile acids are also signaling molecules 
which exert genomic and non-genomic regulations on the body metabolism. One such 
function involves the activation of TGR5, a G protein-coupled receptor (also known as 
M-BAR, GPBAR1). The mechanistic stimulation of TGR5 by bile acids includes the 
accumulation of intracellular cAMP and subsequently activation of the mitogen-
activated protein kinase (MAPK) pathway. The potency of bile acids on TGR5 
activation is positively correlated to the hydrophobicity of the molecule, which is 
ranked as LCA > DCA > CDCA > CA according to an early study [75].  
 
As the expression of TGR5 has been found in several tissues including the gall bladder, 
distal small intestine and the colon, numerous studies on its physiological functions 
have been conducted. Watanabe et al [44] have demonstrated that the bile acid-TGR5 
signaling pathway stimulates energy expenditure by acting in the brown adipose tissue 
in mice via inducing 2-iodothyronine deiodinase (D2), an enzyme which converts 
thyroxine (T4) into tri-iodothyronine (T3). This finding was confirmed in mice with 
high-fat diet feeding and was further applied into the prevention of diet-induced 
obesity. Another physiological effect of the bile acid-TGR5 pathway is related to the 
glucose metabolism. It has been shown that TGR5 stimulates the secretion of glucagon-
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like peptide 1 (GLP1) [76], a member of the incretin family. This protein functions as a 
regulator of the insulin secretion in response to the meal. The physiological significance 
of this finding for human implication is still under investigation. The natural expression  
of TGR5 in the liver is almost negligible according to the previous studies, however the 
homozygous TGR5-/- mice showed a 20% reduction in their bile acid pool size [77]. 
The exact mechanism for this change is still unclear, as CA feeding was unable to exert 
a regulatory effect on any of the enzymes (e.g. Cyp7a1, Cyp8b1, Cyp27a1, etc.) 
responsible for bile acid production in these mice.  
 
 
1.4 CHOLESTEROL METABOLIC DISEASES AND POTENTIAL 
TREATMENT  
 
1.4.1 LXRs, FXR and atherosclerosis 
The therapeutic effects of LXR agonists on atherosclerosis have been demonstrated by 
various animal models. The activation of LXR by GW3965 showed strong reduction of 
atherosclerosis in apoE- and LDLr-knockout mice [78]. This observation has been 
further extended to the other widely used agonist TO-901317 [79]. According to earlier 
studies, LXR activation led to the alteration of plaque composition, which subsequently 
contributed to the attenuation of inflammatory reactions. In addition, reduced levels of 
adhesion molecules and changing in fibrous cap thickness were also observed in the 
studies. Notably, the reduced lesion development did not happen simultaneously with 
the lowering of blood lipid levels, suggesting that the efflux of cholesterol via RCT can 
occur without changing the static lipid level. The atherogenic protective effect of LXRs 
was further confirmed by the loss-of-function study using LXR double knockout mice. 
It was demonstrated that such mice developed atherosclerotic lesions enriched with 
foam cells even under normal chow diet [80]. Despite the beneficial effect of LXR pan 
activation, an LXRβ selective activation is still of great pharmacological interest due to 
the massive hepatic lipogenic effect under LXRα stimulation. It has been demonstrated 
that selective LXRβ activation in mice is sufficient to attenuate atherosclerosis 
development with marginal effects on blood triglyceride levels [81], which provided a 
solid scientific rationale for such approaches.  
 
Compared to LXR agonists, the benefit of FXR activation against atherosclerosis seems 
more controversial and is largely dependent on the experimental conditions. Several 
studies have shown an atheroprotective effect by creating FXR and LDLr-double 
knockout mice [82, 83]. In contrast, FXR and apoE-double knockout mice developed 
severe atherosclerosis with a high mortality rate when fed with atherogenic diet [84]. 
Nevertheless, the atheroprotective effect of FXR stimulation seems to be dependent on 
the improvement of the blood lipid profile [85, 86]. On the other hand, the existence of 
FXR expression on smooth muscle cells of the cardiovascular vessels [87] and 
endothelial cells [88] provides evidence that FXR might actually regulate atherogenic 
events via modulating plaque formation or inflammatory effects. 
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1.4.2 Bile acids, glucose metabolism and type 2 diabetes 
Dyslipidemia, together with obesity, increased blood glucose level and hypertension 
form the criteria of the clinical diagnosis of metabolic syndrome, which is a known risk 
factor for type 2 diabetes [89]. Recent medication for dyslipidemia includes statin, bile 
acid sequestrants, fibrates, nicotinic acid, etc. The link between bile acid modulation 
and lipid homeostasis is mainly due to the signaling pathway of two receptors, namely 
the FXR and TGR5, both of which require bile acids as ligands. Numerous studies have 
provided solid evidence that bile acid-TGR5 activation reduces the blood glucose level 
and improves glucose tolerance in high fat-treated mice [41, 90]. It has been shown that 
TGR5 stimulation by the synthetic ligand INT-777 induces the production of GLP-1 in 
the small intestine, thereby enhancing the postprandial insulin secretion. A similar 
conclusion has been drawn by administering INT-777 to the TGR5 knockout mice, and 
no elevation of GLP-1 has been observed [41]. Another aspect about TGR5 stimulation 
is the increased energy expenditure through the induction of deiodinase in the brown 
adipose tissue, thereby improving the diet-induced weight gain and obesity [44]. This 
observation also provides evidence that activation of TGR5 might be a promising target 
for the treatment of metabolic syndrome.  
 
The link between FXR and glucose metabolism has been proven by several studies 
showing that FXR depletion leads to insulin resistance in the peripheral tissues [91-93]. 
Other studies have also shown that FXR is regulating several genes which are involved 
in the gluconeogenesis pathway, including glucose 6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK). However, the exact mechanism for the 
regulation has not been clarified, also the results seem to be inconsistent and highly 
dependent on the experimental conditions [94-96]. In line with this notion, the 
beneficial effect of FXR agonist on glucose homeostasis is still unclear and partly 
controversial. Therefore, whether FXR stimulation should be considered as a potential 
therapy for alteration in glucose metabolism needs to be validated with more solid 
experimental evidence.  
 
 
1.4.3 Antisense oligonucleotides and cardiovascular diseases 
ASOs are short synthetic single-stranded nucleotide polymers, which usually contain 
15-25 nucleotides in length. These single-stranded polymers have the ability to 
hybridize with the target RNA via Watson-Crick base pairing, and activate the 
endogenous RNase H to hydrolyze the target RNA strand. This results in the reduction 
of mRNA expression and subsequently protein levels of the target gene [97-99]. Since 
the approval of the first generation ASO, there has been a growing interest to improve 
the pharmacokinetic and pharmacodynamic properties of the first generation ASOs. 
Among all the attempts, adding a 2’-O-methoxyethyl (MOE) or a 2’-O-methyl (Me) 
group to the ASO strand has been proven to provide higher biological stability, greater 
in vivo potency and less toxicity [100]. Because of the ability to inhibit specific targets 
with a broad range of selection on the target, the ASO technique has also been used for 
the design of drugs against dyslipidemia and cardiovascular diseases. Targets involved 
in preclinical or clinical studies include apoB-100, PCSK9 and Lp(a) [101].  
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2 AIMS 
 
The general aim of this thesis is to investigate and better understand the regulatory 
effect of bile acids and nuclear receptors on cholesterol homeostasis under the 
cholesterol overloading condition. 
 
The specific aim for each project is described as: 
 
 
Paper I To characterize the cholesterol metabolic profile induced by selective 
activation of LXRβ, in particular to study the regulatory effect mediated 
by LXRβ on intestinal cholesterol absorption and the blood lipoprotein 
profile. 
 
Paper II To evaluate the regulatory effect of muricholic acid on bile acid 
synthesis, and to re-characterize the phenotype of Cyp8b1-/- mice 
regarding bile acid metabolism.  
 
Paper III To explore the therapeutic potential of CA depletion on systemic 
cholesterol overloading by using second generation antisense 
oligonucleotides. 
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3 MATERIALS AND METHODS 
 
3.1 ANIMALS AND TREATMENTS 
 
Paper I 
Male mice on a C57BL/6J background (6-9 weeks of age, Taconic A&B, Denmark) 
were used for the experiment and housed in a pathogen-free facility with a regular 
light/dark circle of 12h/12h. Each experimental group contained 4-6 individuals. Mice 
were either fed with a standard diet (SDS, Germany) or 0.2% cholesterol-enriched diet 
(wt/wt, Harlan Teklad, USA) with free access to water for 2 weeks before the 
termination. When necessary, the LXR agonist GW3965 was given at 40mg/kg/day for 
4 days by oral gavage. All mice were fasted for 4 hours before the termination for the 
collection of gallbladder bile. All animal experiments were approved by the ethical 
committee of Karolinska Institutet. 
 
 
Paper II 
Inbred female mice on a C57BL/6J background (8-10 weeks of age, genotype:  
Cyp8b1-/- and the litter mates Cyp8b1+/+) were housed in a pathogen-free facility under 
a light/dark circle of 12h/12h with free access to standard food and water unless 
otherwise specified. For each treatment group, 6 mice were used and received single 
doses of saline (100 μL) with or without AMP (100mg/kg/day) by gavage. Another 
four groups of Cyp8b1-/- mice (n=3-6) were used and given oral gavage of 200μL saline 
solution with AMP (100mg/kg/day) and supplemented with CA, CDCA or DCA at a 
concentration of 9 μmol/kg/day. All gavages were given at 9am for 3 continuous days, 
with a boosting dose at 5pm on day 3. Before the end of the experiments, all mice were 
fasted for 4 hours with free access to water. All animal experiments were approved by 
the ethical committee of Karolinska Institutet. 
 
 
Paper III 
Male mice on a C57BL/6J background (around 6 weeks of age, Taconic A&B, 
Denmark) were housed in a pathogen-free facility under a light/dark circle of 12h/12h 
with free access to water and food during the treatment with the ASOs. Five or six mice 
were used for each treatment group. The ASO substances were given by intra-
peritoneal injection (IP) twice per week at 50mg/kg/week (wt/wt) for six weeks. For 
dietary studies, mice were fed with a 0.2% cholesterol diet, (wt/wt, Harlan Teklad, 
USA) for 2 weeks in parallel to the ASO treatment before the sacrifice. All mice were 
fasted for 4 h with free access to water before the sacrifice. All animal experiments 
were approved by the ethical committee of Karolinska Institutet.  
 
 
3.2 GENE EXPRESSION 
Total RNA was purified from individual samples of liver or small intestine, and the 
concentration of RNA was determined. After that, 1µg of total RNA was used for the 
synthesis of cDNA. The relative expression levels of target genes were determined by 
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real-time PCR (7500, Applied Biosystems, USA) and calculated in relation to the 
house-keeping genes HPRT or cyclophilin.  
 
 
3.3 PROTEIN EXPRESSION 
Total protein was purified from individual or pooled samples of liver or small intestine. 
For Western blotting, 4-12% gradient bis-tris gels were used for the separation of the 
protein. After blotting, the membrane was incubated with primary and secondary 
antibodies. Results were recorded using a Molecular Imager® camera (Bio-Rad, USA). 
Densitometry analyses were performed for quantification of the results. Detailed 
information of the antibodies can be obtained from method part of paper I-III.  
 
 
3.4 DIETARY INTESTINAL CHOLESTEROL ABSORPTION 
Mice were given 100µL peanut oil mixed with 1 µCi[4-14C] cholesterol (Amersham 
Bioscience, USA) and 2 µCi [5,6-3H] β-sitostanol (American Radiolabel Chemical Inc., 
USA) by oral gavage. After the gavage, each mouse was caged separately for 24 hours 
to allow the fecal collection. The lipid in the feces was then purified using the Folch 
method (chloroform: methanol 2:1, v/v).  
 
 
3.5 FECAL NEUTRAL STEROIDS AND BILE ACIDS 
Neutral steroids and bile acids were purified from 0.5g feces homogenates for each 
mouse using hexane and ether methods, respectively [102]. The final extracts were then 
analyzed by GC. 
 
 
3.6 LIVER CHOLESTEROL AND BILE ACIDS 
Cholesterol and bile acids were purified from 1g of liver tissue with Folch and ether, 
respectively. The final extracts were then analyzed by GC-MS. 
 
 
3.7 BILIARY CHOLESTEROL AND BILE ACIDS 
Cholesterol and bile acids were purified from 2µL of gallbladder bile using Folch and 
ether, respectively. The final extracts were then analyzed by GC-MS. 
 
 
3.8 SERUM LIPOPROTEIN CHOLESTEROL 
Serum lipoprotein cholesterol was analyzed by FPLC using size-exclusion 
chromatography [102]. 
  
3.9 STATISTICS 
Statistical analyses were performed by STATISTICA version 9 and GraphPad Prism 
5.04 Software. Detailed methods can be obtained in each paper. 
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4 RESULTS AND COMMENTS 
 
4.1 PAPER I: LXRBETA ACTIVATION INCREASES INTESTINAL 
CHOLESTEROL ABSORPTION, LEADING TO AN ATHEROGENIC 
LIPOPROTEIN PROFILE                                                                                                  
 
It has been demonstrated that the inhibition of intestinal cholesterol absorption alone or 
with other lipid lowering drugs in humans leads to clear atheroprotective effects [103-
105]. Studies have been focused on the mechanism of how LXR stimulation leads to 
reduced intestinal cholesterol absorption, however little is known about the individual 
role of LXRα and LXRβ on the regulation of cholesterol absorption. In this study, we 
have investigated the significance of LXRα and LXRβ on the absorption of cholesterol 
in mice, and evaluated the subsequent effects on cholesterol and bile acid metabolism. 
 
 
Separate activation of LXRβ induces dietary cholesterol absorption and 
elevates serum apoB-containing particles in LXRα-/- mice. 
A major concern of using LXR agonists in treating atherosclerosis is the dramatic 
elevation of serum triglycerides when LXRα is activated. Therefore, a dissected LXRβ 
agonist might be of great potential value in terms of therapeutic purpose. In line with 
this notion, we investigated the effect of selective LXRβ activation by using the 
synthetic LXR pan agonist GW3965 in LXRα-/- mice. As observed in the study, a 
significant enhancement of dietary cholesterol absorption was shown only in LXRα-/- 
mice after 4 days of 0.2% cholesterol diet with or without GW3965. This is in sharp 
contrast with the other two genotypes used in the same study, the WT and LXRβ-/- 
mice, which showed marginal effects of dietary cholesterol absorption under the same 
treatment. Results from fecal neutral sterol measurements confirmed the absorption 
data, as the fecal neutral sterol output was reduced solely in the LXRα-/- mice under 
0.2% cholesterol or/and GW3965. However, changes on fecal neutral sterols can also 
be due to the different cholesterol output through the bile, therefore we investigated 
whether that could be the explanation. According to the experiment, no changes were 
found between the three genotypes on biliary cholesterol excretion. Taken together, 
these results suggested an increased dietary cholesterol absorption in the gut, which led 
to a decrease in fecal lipid output.  
 
The above observations are accompanied by elevated total and apoB-lipoprotein 
cholesterol in the serum when mice were challenged by 0.2% cholesterol and/or 
GW3965. According to our observation, the total lipoprotein cholesterol was almost 
doubled in all genotypes of mice when treated with 0.2% cholesterol and GW3965, 
although the individual lipoprotein fraction differed between the genotypes. It seemed 
that activation of LXRs and LXRα mainly resulted in the increase of the HDL fraction, 
while LXRβ activation resulted in LDL cholesterol induction in the blood. Based on the 
above two observations, we suggested that the separate activation of LXRβ should be 
used with caution as adverse effects might appear. Consequently, it is of great 
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importance that the physiological effects of LXRα and LXRβ are carefully evaluated in 
order to avoid the side effects while maximizing the advantage for the therapeutic 
purpose. 
 
 
Compensatory effects of LXRα and LXRβ in the regulation of cholesterol 
metabolic genes. 
This study also reveals the compensatory effect of LXRα and LXRβ in the regulation of 
the intestinal genes ABCG5 and NPC1L1. The loss of either subtype did not jeopardize 
the regulatory effect on the other subtype, as both LXRα-/- and LXRβ-/- mice fed with 
0.2% cholesterol with GW3965 showed a downregulation of NPC1L1 and an 
upregulation of ABAG5. Interestingly, the 0.2% cholesterol diet alone did not 
markedly affect Npc1l1 gene regulation, and when compared to the dietary cholesterol 
absorption, the downregulation of NPC1L1 by 0.2% cholesterol+GW3965 did not 
correlate to the changes in cholesterol absorption. An explanation for the discrepancy 
could be that the transcriptional level of NPC1L1 might not reflect the real activity of 
this cholesterol transporter. Studies have revealed that the crucial step of Npc1l1 in 
cholesterol uptake is the shuttling of the protein from the endocytic recycling 
compartment to the plasma membrane, and internalization before transporting 
cholesterol into the cell [106, 107]. Therefore, the rate of cholesterol absorption would 
be affected not only by the expression level of NPC1L1, but also by the modifications 
of the other steps involved in this process (Figure 4). 
 
 
LXRα and LXRβ modify bile acid composition and excretion in response 
to the ligand stimulation. 
Bile acids are crucial for the regulation of the dietary cholesterol absorption due to their 
amphipathic nature which facilitates lipid solubility. The ratio between the hydrophobic 
bile acid CA and its hydrophilic counterpart β-MCA is closely related to the cholesterol 
absorption rate. Generally speaking, the higher the ratio of CA/β-MCA, the more 
cholesterol gets absorbed in the intestine. In line with this notion, we analyzed the 
biliary bile acid composition of the mice as differences of cholesterol absorption have 
been detected. Under 0.2% cholesterol diet, the ratio between CA and β-MCA went 
down in WT and LXRβ-/- mice, indicating a more hydrophilic bile acid pool during the 
feeding, while the ratio in LXRα-/- showed only moderate changes. When GW3965 was 
given in addition, the bile acid composition in WT and LXRβ-/- mice showed further 
hydrophilic properties in comparison to the LXRα-/- mice. Thus, the bile acid 
composition of LXRα-/- mice had the highest hydrophobicity among all genotypes, 
which was in line with its highest cholesterol absorption rate. It is of particular interest 
that LXRα-/- mice might have a more hydrophobic bile acid profile, as the fecal bile 
acid excretion of these mice contained more DCA and less MCA than the other two 
genotypes. 
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Figure 4. Proposed mechanisms of the effects of LXRα and LXRβ on the regulation of 
cholesterol transport processes in the small intestine. LXRα and LXRβ similarly regulate the 
expression of cholesterol transporters, reducing the mRNA of Npc1l1 while elevating Abcg5/g8 
and Abca1. These changes lead to the reduction of cholesterol uptake and enhanced cholesterol 
excretion. Meanwhile, selective activation of LXRβ increases cholesterol uptake through an 
unknown pathway, which is counteracted by LXRα. 
 
 
 
4.2 PAPER II: MURICHOLIC BILE ACIDS ARE POTENT REGULATORS 
OF BILE ACID SYNTHESIS VIA A POSITIVE FEEDBACK 
MECHANISM 
 
Several animal models have been used to investigate the individual role of bile acids on 
their activation of FXR and other regulatory factors, but the exact role of each bile acid 
on their own homeostatic regulation remains to be elucidated [30, 108-110]. In this 
study, we used ampicillin (AMP) to eliminate the production of secondary bile acids in 
wild type (WT) and Cyp8b1-/- mice (KO) in order to gain a close look at the individual 
bile acids and their regulatory functions. In addition, we also fed KO mice with various 
bile acids in parallel to the AMP treatment, so as to compare the impact of exogenous 
bile acid feeding on the bile acid regulation. 
 
 
Effects of ampicillin on bile acid synthesis and excretion in WT and KO 
mice. 
WT mice fed with AMP dramatically induced their Cyp7a1 expression for 4 fold as 
compared to the control group. The expression level of Cyp7a1 mRNA in the WT-
AMP group was similar to that in the KO group, regardless of the treatment. Analysis 
on Cyp7a1 protein activity confirmed the above observation. We then analyzed the two 
major bile acid regulatory factors, SHP and Fgf15. In the intestine of WT mice, both 
receptors were downregulated at the mRNA level with AMP treatment. The expression 
levels of both receptors in the KO mice, regardless of the treatment, were similar to the 
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ones in AMP-treated WT mice. Marginal changes on SHP were observed in the liver. 
These data suggest that the synthesis of bile acids in the liver was significantly 
increased in WT+AMP mice.  
 
In accordance with the above observation, we continued to investigate the fecal 
excretion of bile acids in WT+AMP mice, as induced liver bile acid synthesis is likely 
to result in an enhanced output on fecal bile acid excretion. Surprisingly, the excretion 
of fecal bile acid was almost completely eliminated in AMP treated mice for both the 
WT and the KO group. This is in drastic contrast to the situation in the non-treated 
groups, as KO mice showed an almost doubled bile acid excretion in the feces as 
compared to the WT mice. Such result could only be due to the dramatic increase in 
bile acid reabsorption in the distal ileum, as the hepatic bile acid synthesis has been 
enhanced after the AMP treatment. As confirmed by Western-blotting, the Asbt 
expression in AMP treated mice was much higher than in the non-treated group, 
indicating enhanced bile acid reabsorption. Taken together, these data highly suggest 
that the total mass flow of bile acid in the enterohepatic circulation is increased several 
fold in AMP treated mice, and that this phenotype is most likely due to an impaired 
FXR-signaling.   
 
The liver bile acid analysis revealed an increase of the total bile acid in the WT+AMP 
group, which was similar to the levels of KO mice with or without AMP. The increased 
amount of bile acid is mainly due to the elevation of hydrophilic bile acids (MCAs and 
UDCA), whereas the changes on hydrophobic bile acids (CDCA, DCA and LCA) and 
CA were marginal. It is worth noticing that DCA can only be detected in the WT+AMP 
group. Based on the above data, it is obvious that the differences in CA cannot be 
explained by the upregulation of bile acid synthesis in the AMP groups. Therefore the 
question remains whether loss of DCA or increase of MCA concentration is responsible 
for the bile acid synthesis changes. 
 
 
Effects of bile acid administration on bile acid synthesis and excretion 
in KO mice. 
In order to gain a deeper understanding of the regulatory effect of individual bile acids, 
we treated the KO mice with CA, CDCA, or DCA in parallel to the AMP gavage. The 
advantage of such an approach is the elimination of the endogenous primary bile acid 
CA, and the secondary bile acids DCA and LCA. As expected, the Cyp7a1 mRNA 
levels were suppressed by 81% and 82% in the CA and DCA treated groups, 
respectively. In contrast, the CDCA treatment was less effective as it reduced Cyp7a1 
mRNA only by 59%. The Cyp7a1 mRNA changes might be due to the hepatic SHP, as 
inverse correlations were seen between the hepatic SHP and Cyp7a1 in all treatment 
groups. Intestinal expression of SHP showed elevated expression levels in all bile acid 
treated groups, a pattern also seen for intestinal Fgf15 mRNA. Finally, Asbt mRNA 
revealed 45% reductions in the CA and CDCA groups while a stronger 65% reduction 
was observed in the DCA group. The Asbt protein expression was suppressed by 40% 
in the CA and the DCA groups while it was 60% suppressed in the CDCA group.  
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The liver total bile acid concentration has been reduced by 30-34% in CA and DCA-
treated mice, whereas the amount has been increased by 30% in CDCA-treated mice as 
compared to WT mice. An 89% reduction of CDCA was found in both CA and DCA 
treated groups. These observations indicate that the potent FXR activator CDCA is 
unlikely to explain the Cyp7a1 suppression in these two groups. In addition, DCA was 
detectable in the DCA-treated group, which had similar Cyp7a1 expression as the CA 
group. This observation further eliminates the possibility that DCA is the explanation 
for the induction of bile acid synthesis. By contrast, total hydrophilic bile acids (α-, β-
MCAs and UDCA) were reduced by 39% and 34% in the CA- and DCA groups, 
respectively, while a 22% increase was detected in the CDCA group. Indeed, the α-
MCA content was down by 68% in both CA and DCA treatment, while a 3-fold 
elevation of α-MCA was detected in the CDCA-treated group. These results suggest a 
general significance of the regulatory effect of MCA on bile acid synthesis, in 
particular within the positive feedback which counteracts FXR signaling (Figure 5). 
 
 
Figure 5: Schematic diagram of BA metabolism in mice. The bile acid flow in Cyp8b1-/-mice is 
illustrated with green arrows, while magenta arrows show the increase or decrease of the bile 
acids. As Cyp8b1-/-mice lack CA and DCA, CDCA and MCA production is increased in the 
liver, which then enter the small intestine. As the absorption of these bile acids in the ileum 
increases in parity, presumably via Asbt-dependent and -independent mechanisms, MCAs exert 
FXR-antagonistic effects in the enterocytes, which override the agonistic effects of CDCA, 
thereby strongly reducing ileal FGF15 expression. This de-represses Asbt expression, which 
increases BA absorption enlarging the BA pool that will be further enriched with MCAs from 
hepatic conversion of CDCA to MCAs. Likewise, in the hepatocyte, MCAs will exert FXR-
antagonistic effects de-repressing Cyp7a1 expression, thereby increasing hepatic BA synthesis. 
In parallel, reduced FGF15 signaling from the gut to liver may contribute to de-repress hepatic 
Cyp7a1 expression, although evidence for that is circumstantial. 
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4.3 PAPER III: SECOND GENERATION ANTISENSE 
OLIGONUCLEOTIDES PREVENT ACCUMULATION OF LIVER 
CHOLESTEROL BY INHIBITING CHOLIC ACID SYNTHESIS 
 
In paper II, it was found that the hydrophilic bile acid MCA exerts positive feedback 
regulation on bile acid synthesis, and might counteract the agonistic effect of 
hydrophobic bile acids such as CA or DCA. In this study, we modulate the CA 
production by using second generation antisense oligonucleotides (ASOs) against 
Cyp8b1, the key enzyme for CA production in order to evaluate their pharmacological 
potential as a target for maintaining cholesterol homeostasis.  
 
 
Effects of ASOs on cholesterol and bile acid metabolic parameters in 
mice under normal diet. 
A total of ten different ASOs were used for the evaluation of their respective efficacy. 
The effects of ASOs were measured initially by the level of Cyp8b1 mRNA after 6 
weeks of treatment. According to the results, the most effective ASO, ASO-81, 
suppressed Cyp8b1 mRNA by 75% compared to the control group. A similar reduction 
in Cyp8b1 expression was also shown at the protein level. Importantly, no liver toxicity 
was detected with ASO-81, indicating that the compound was well tolerated during the 
treatment.  
 
The analysis of the biliary bile acid composition revealed that the CA fraction was 
reduced in the ASO-81 treated group by almost 50% as compared to the control group. 
In contrast, the proportion of MCA and CDCA was increased in ASO-81 treated mice. 
This resulted in a dramatic reduction of the CA/β-MCA ratio in the ASO-81 group (1.0 
vs 3.3 in the control group). These results clearly indicate the potency of ASO-81 in 
eliminating the CA production in mice. Similar to Cyp8b1-/- mice, the ASO-81 treated 
mice were characterized by a less hydrophobic bile acid profile with a higher 
percentage of MCA and UDCA in the bile acid pool. Such a bile acid profile is highly 
in favor for the reduction of cholesterol absorption, which is crucial in maintaining a 
good balance of cholesterol homeostasis. 
 
The expression of genes involved in bile acid metabolism was also affected by the ASO 
treatment. Downregulation on ileal SHP and Fgf15 mRNA was detected in the ASO-81 
treated group, while induction on ileal ASBT was found in parallel. These results 
suggest the increase of bile acid reabsorption through the enterohepatic circulation 
during the ASO treatment. Similar results were found in the Cyp8b1-/- mice, of which 
the CA production was depleted genetically.  
 
 
Effects of ASO-81 on liver cholesterol accumulation and serum 
lipoprotein cholesterol profiles after dietary cholesterol challenge. 
As Cyp8b1-/- mice showed marked resistance to cholesterol overload due to the 
relatively higher bile acid turnover and low cholesterol absorption, we evaluated the 
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effects of ASO-81 on liver cholesterol metabolism under 0.2% cholesterol feeding. The 
treatment reduced the liver cholesterol content by 50% compared to the control group. 
This was mainly due to the reduction of esterified cholesterol in the liver. 
Simultaneously, a slight increase of free cholesterol was observed. In line with the 
reduced liver cholesterol content, we observed a 70% decrease of VLDL cholesterol in 
the serum under the ASO-81 treatment compared to the control group, while no major 
changes were found in the LDL cholesterol fraction. A mild increase of HDL-
cholesterol was also detected with ASO-81 treatment. This is in line with the liver 
cholesterol finding, as reduced levels of cholesterol in the apoB-containing lipoproteins 
could be recognized as an expression for a state of relative ‘cholesterol deficiency’. 
 
In the Cyp8b1-/- mice, an important phenotype is the upregulation of Cyp7a1 due to the 
lack of feedback suppression by CA elimination. Compellingly, treatment of ASO-81 
did not completely phenocopy the Cyp8b1-/- mice, and one striking difference 
represented the consistent level of hepatic Cyp7a1 in the ASO-81 mice. Despite the 
upregulation of bile acid regulatory factors, namely the SHP and Fgf15 expression, the 
liver bile acid synthesis remained consistent compared to the control group. This 
observation could be explained by the CA in the ASO-81 treated mice, which is 
different from the Cyp8b1-/- mice. Another explanation might be due to the complex 
regulatory pathways of Cyp7a1, and the FXR-mediated feedback mechanism only 
represents one such approach.  
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5 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
 
The present thesis extends the knowledge of cholesterol metabolism regulation by 
nuclear receptor LXRs and bile acids, two major players in the homeostasis of 
cholesterol in the body. Although such topics have been intensively studied at a broader 
scope, lots of detail mechanisms still remain unclear.  
 
It has been more than a decade since the discovery of LXRs as oxysterol receptors by 
the in vitro study [57]. An early study has demonstrated that impaired synthesis of  
24S-, 25- and 27-hydroxycholesterol resulted in disrupted LXR signaling upon 
cholesterol feeding in mice [111]. However, this theory was recently challenged by the 
creation of mice transgenic for human cholesterol 24-hydroxylase with enhanced 
production of 24-hydroxycholesterol [112]. In this model, LXR signaling was not 
dramatically enhanced despite the dramatic elevation of its natural endogenous ligand. 
Nevertheless, numerous studies have been intensively conducted onwards in order to 
clarify the exact metabolic role of LXRs in lipid metabolism. Although the expression 
of both LXRs has been found in many tissues, it is important to note that the two 
subtypes regulate gene transcription in a tissue-specific and subtype-specific manner. 
For this reason, animal models with specific knockout have been proven to be more 
useful. One major function of LXRs, in particular LXRα, is to maintain the homeostasis 
of lipid metabolism. A subtype specific knockout of LXRα in mice was first described 
in 1998 by Peet et al [113]. In this animal model, the natural resistance to cholesterol 
overloading was disrupted when mice were fed with 2% cholesterol diet. This 
observation was attributed to the lack of Cyp7a1 upregulation by LXRα in the liver, 
which is otherwise upregulated upon high cholesterol challenge. Interestingly however, 
LXRβ knockout mice failed to display a similar phenotype under the same cholesterol 
loading condition, indicating the different physiological functions of the two subtypes 
[114]. Later on, the biological functions of LXRs were extended to cholesterol uptake, 
absorption, excretion and reverse transportation as more genes have been discovered 
under direct LXRs governance [63, 115-117].  
 
The massive improvement of LXR stimulation on lipid homeostasis has aroused great 
interest in translating the nuclear receptor into a potential therapeutic target against 
atherosclerosis. However, the initial attempt by using first generation LXR synthetic 
agonists such as TO-901317 and GW3965 was largely disappointing due to the strong 
elevation of lipogenesis by the activation of LXRα, resulting in adverse effects such as 
tryglyceridemia and fatty liver disease [64]. These observations give the scientific 
rationale for the creation of a selective activation on LXRβ, especially when results 
have shown strong atheroprotective effects of LXRβ without induction of lipogenesis 
[81, 118, 119]. In line with the notion, we used selective LXRα or LXRβ knockout 
mice and compared the separate activation of either subtype on cholesterol and bile 
acid metabolism by using the synthetic agonist GW3965. We demonstrated that 
selective activation of LXRβ might generate effects such as enhanced cholesterol 
absorption with elevated apoB-lipoprotein cholesterol in the circulation. In addition, 
such an approach also led to decreased fecal neutral sterol output without affecting the 
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biliary sterol excretion. A more hydrophobic profile on bile acid excretion was also 
discovered by selective LXRβ activation [120]. These observations raised the concern 
that selective LXRβ activation should be used with caution as adverse effects might 
exist.  
 
Another approach to avoid massive lipogenesis is the tissue selective activation of 
LXRα, which has been created and thoroughly investigated by Lo Sasso et al [121].  In 
their study, the authors demonstrated tissue specific effects of LXRβ on ABCG5 
regulation, without induction of the hepatic target genes of LXRs. It further unraveled 
the key role of the small intestine in the context of cholesterol homeostasis by showing 
the reduced absorption of cholesterol during the intestinal LXRα specific induction. 
Taken together, the numerous experimental data provide a solid scientific rationale for 
the development of LXR agonists for an atheroprotective purpose. Meanwhile, safety 
concerns and a more careful dissection of isoform specific activation remain 
highlighted before the mature translation of the LXR agonists from bench to bedside. 
 
In addition to the nuclear receptor LXRs, another major player in the homeostasis of 
cholesterol is the bile acids, governing the elimination pathway of excess cholesterol. 
Manipulation of the bile acid production generates a significant impact on Cyp7a1 and 
bile acid synthesis due to the signaling intensity change of the FXR pathway. 
Interestingly, studies on humans and mice showed a different affinity of bile acids to 
FXR. While CA acts as the strongest ligand for FXR in mice, human FXR reacts 
strongly to CDCA [122, 123]. In mice with genetic depletion of CA production 
(Cyp8b1-/- mice), the bile acid synthesis was dramatically elevated resulting in an 
increased total bile acid pool size [30]. The phenotype was ascribed to the elimination 
of CA, a strong agonist for FXR at least in mice. However, the limitation of such an 
explanation is that the effect of secondary bile acids such as DCA has been largely 
ignored. In addition, whether the significant increase of MCAs in these mice 
contributes to the phenotype is unknown.  
 
We investigated this possibility by using antibiotics to eliminate the secondary bile acid 
production by WT and Cyp8b1-/- mice. We found that CA elimination could not be the 
possible explanation for the upregulation of bile acid synthesis in Cyp8b1-/- mice, as 
similar levels of Cyp7a1 were detected in WT+AMP and KO mice, whose CA levels 
differed dramatically. By giving exogenous bile acids to AMP-treated Cyp8b1-/- mice, 
we could systematically exclude DCA as the potential explanation for the phenotype. 
Instead, we found that by counteracting the FXR stimulation, the increase in 
hydrophilic bile acids (MCAs and UDCA) was the real driving force for the elevated 
bile acid synthesis in Cyp8b1-/- mice. This observation indicates that by modulating the 
enterohepatic circulation of bile acids, the positive feedback mechanism regulates bile 
acid homeostasis without employing the hormonal effect of Fgf15, although such effect 
is most likely to exist. This finding is of fundamental importance for the understating of 
bile acid metabolism in both humans and mice, as the Fgf15/19 negative feedback 
mechanism is believed to operate in both species. Our proposed positive feedback 
mechanism of MCA in the context of bile acid synthetic regulation could possibly be 
extended to the germ-free and bile duct ligated rodents. The finding is in line with the 
recent publication from Sayin et al that addresses the importance of MCA for the bile 
acid metabolism in mice [124]. In their study, they reveal the profound systematic 
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effect of gut microbiota not only on local secondary bile acid production, but also on 
the synthesis of bile acids in the liver.  
 
More studies on intestinal bacteria reveal the close relation between gut microbiota and 
other lipid metabolic diseases. The imbalanced bacterial population caused by the high-
fat diet is a trigger for the development of obesity [125, 126], diabetes [127, 128] and 
hypercholesterolemia [129] in rodents. In humans, an imbalanced gut microbiota has 
been reported in patients with diabetes and inflammatory bowel diseases [130, 131]. A 
recent study by Islam et al demonstrated that CA feeding in rats caused a bacterial 
repopulation similar to the one found in the high-fat fed rats [132]. This observation 
improves our understanding on the relation between gut bacteria, bile acids and 
metabolic diseases. 
 
The thorough characterization of cholesterol metabolism by using various animal 
models opens up the gate for the profound understanding of human disease conditions, 
in particular diseases related to lipid metabolism such as atherosclerosis. New 
therapeutic pharmaceuticals combine modern drug design technology with a specific 
target on atherosclerosis, creating products which are potentially useful for the 
treatment of atherosclerosis. One such approach is to use ASOs, a synthetic DNA 
chimeric compound. Clinical trials on the efficacy and safety of such drugs have been 
carried out to evaluate their potential therapeutic value. To date, the most advanced 
ASO in the clinical development for dyslipidemia is a 2’-O-methoxyethyl 
phosphorothioate 20-mer ASO with the common name mipomersen. Its primary 
function is to inhibit the synthesis of apoB-100 in the liver, which then results in a 
reduced serum LDL cholesterol level in animal models and clinical trials [133-135]. 
Another promising novel ASO target is PCSK9, the use of which also lowers the blood 
LDL cholesterol as shown in preclinical studies [136, 137]. We also followed a similar 
approach by using an ASO targeting Cyp8b1 in mice, as an early study from our group 
showed that eliminating CA production was associated with an atheroprotective effect 
in apoE knockout mice [31]. We observed a dramatic reduction of the CA percentage in 
the mice treated with ASO-81, although the elimination of CA by ASO was not as 
drastic as in the Cyp8b1-/- mice. The phenotype observed in the treated mice also 
included the prevention of liver cholesterol accumulation under high cholesterol 
loading, and a reduced serum apoB cholesterol profile. The above observations reveal 
the potential role of such an approach for the development of atheroprotective 
therapeutics, although further studies are still needed, including sequence screening and 
efficacy evaluation for the human counterpart of ASO-Cyp8b1. Other potential targets 
including apoC-III and Lp(a) for the ASO drug design are also under development.  
 
In summary, the regulation of cholesterol homeostasis represents several complex 
interactions between nuclear receptors and bile acids. A thorough understanding of how 
each pathway is regulated is of benefit for the development of novel therapeutic 
approaches for dyslipidemia, cardiovascular disease and diabetes. With the help of 
modern drug design technology, a combined expertise of medicine and pharmacology 
would help to design a specific drug with minimized adverse effects, which will 
eventually refine the treatment of diseases such as atherosclerosis and other 
dyslipidemia-related disorders. 
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6 CONCLUSIONS 
 
In the present thesis, we intended to gain a deeper understanding of how cholesterol 
and bile acids regulate cholesterol homeostasis. We identify the individual function of 
LXRα and LXRβ in the regulation of cholesterol absorption and serum lipid profile, 
and find that the separate activation of LXRβ as a therapeutic approach for an anti-
atherogenic purpose should be used with caution as it enhances the cholesterol 
absorption in the small intestine and raises the apoB-lipoprotein cholesterol in the 
circulation (paper I). In addition, the phenotype of Cyp8b1-/- mice in terms of bile acid 
metabolism has been reinvestigated in the thesis, to which a novel positive feedback 
mechanism of MCAs on bile acid synthesis has been proposed (paper II). The finding 
of MCAs as important bile acid synthesis regulators provides new insights into the bile 
acid homeostasis, and mouse models such as the Cyp8b1-/- mice become a more 
attractive experimental tool due to the massive increase of their MCAs. In line with this 
notion, we also explore the potential of creating such mouse models from WT 
background with second generation ASOs against Cyp8b1 mRNA. To our knowledge, 
this is the first report for such an approach with successful results in generating Cyp8b1 
knockdown animal models (paper III). The above findings in this thesis reveal a highly 
potent mode of interaction between nuclear receptors and bile acids in the regulation of 
cholesterol homeostasis, and are therefore likely to be important in understanding the 
lipid metabolism in both preclinical and clinical conditions. 
 26 
7 ACKNOWLEDGEMENTS 
 
The past five years of this PhD journey have been an extraordinary experience in my 
life both within and outside academia. Therefore I take this opportunity to express my 
sincere gratitude to everyone and everything that helped me, in one way or another, in 
the path of growing up during this time. In particular, I would like to thank: 
 
My supervisor, Dr. Gösta Eggertsen, for all the time you spent with me for project 
discussions, for manuscript corrections, and for exchanging all the brilliant scientific 
inspirations. In addition, thank you for all the help you offered during my first year of 
arrival, for the Chinese dinner cooking, for the mushroom picking, for everything you 
did to speed up my integration into this lovely country.  
 
My co-supervisor, Dr. Paolo Parini, for involving me in your weekly group meeting, 
for project discussions, critical reading of my manuscripts, for sharing your knowledge 
on medical statistics, and for the entire positive attitude. Also, thank you for being 
patient with me and tolerating my stubbornness during the discussions.  
 
My co-supervisor, Dr. Mats Gåfvels, for teaching me the importance of being 
independent. It is proven to be so valuable for my future development both within and 
outside academia. Also, thank you for correcting my thesis. 
 
To Dr. Rachel Fisher, thank you for being my mentor. Also, thank you for inviting me 
to your nice apartment and for the wonderful afternoon cake! 
 
To Dr. Knut Steffensen and Dr. Mats Rudling, thank you for the fruitful 
collaborations and for believing in me. 
 
To all the present and past officemates: Vera Tillander, Tina Kannisto, Diba Ahmed, 
Dr. Naama Kenan Modén, Osman Ahmed, Ahmed Saeed, Treska Hassan, Dr. 
Zhao-Yan Jiang, Dr. Yufang Zheng, Dr. Davide Gnocchi, Dr. Lisa-Mari Mörk, 
Dara Deegan, Dr. Marjan Shafaati, Dr. Katharina Slätis, Dr. Ann Båvner. The 
weekdays would have been harder without your company . As I wrap thing up on my 
table, the giant pile of bottles just becomes more visible in the corner-- It’s time for 
cake and ice cream again! 
 
To my labmates: Maria Olin, Mikaela Bodell, Ninawa Aho. Thank you for all the 
technical support on methodology questions, practical help in finding reagents, and for 
all the pipetting chats, which made the tedious experiments more interesting.  
 
To my animal roommates: Lilian Larsson, Dr. Matteo Pedrelli, Dr. Maura Heverin, 
Zeina Ali. Thank you for being nice to my mice by giving them a spacious growing 
environment, really appreciate that! 
 
To all the other colleagues in and outside the division: Dr. Ingemar Björkhem, Dr. 
Stefan Alexson, Dr. Anders Helander, Dr. Ulf Diczfalusy, Anita Lövgren 
   27 
Sandblom, Dr. Ulla Andersson, Hanna Nylén, Dr. Camilla Pramfalk, Dr. 
Malgorzata Strozyk, Dr. Jenny Flygare, Dr. Anna-Klara Rundlöf, Dr. Ylva Bonde. 
Thank you for all the help and for all the good time together. 
 
To our wonderful secretary, Jenny Bernström, thank you for all the administrative 
help which saved me lots of time and effort! 
 
To my dear friends: Ying, Sonal, Sameer, Devesh, Gökce, Esra, Nina, Melroy, Bea, 
Ashwin for the kind supports and suggestions you gave when I needed them. And for 
all the wonderful moments and fun we shared during the past 5 years.  
 
To my parents, Dongping and Caiyu. Thank you for allowing me to realize my 
potential, and for teaching me the value of education and hardworking. I would have 
not reached this far without your constant contribution. 
 
To my dear husband, Erwin. Life has never been sweeter since we are together. Thank 
you for being who you are, for always standing by my side with care and support, and 
for making me laugh even during the bad days. I feel so blessed to have you in my life!  
 
To life. Tomorrow the sun will always rise and shine. 
 
 
 
 
 28 
8 REFERENCES 
 
1 Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of 
cholesterol and low density lipoprotein homeostasis in different animal species, 
including humans. Journal of lipid research 1993; 34: 1637-59. 
2 Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, 
Ebrahim S. Statins for the primary prevention of cardiovascular disease. The Cochrane 
database of systematic reviews 2011: CD004816. 
3 Gill S, Chow R, Brown AJ. Sterol regulators of cholesterol homeostasis 
and beyond: the oxysterol hypothesis revisited and revised. Progress in lipid research 
2008; 47: 391-404. 
4 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. The Journal of clinical 
investigation 2002; 109: 1125-31. 
5 Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J. Crystal structure of 
the catalytic portion of human HMG-CoA reductase: insights into regulation of activity 
and catalysis. The EMBO journal 2000; 19: 819-30. 
6 Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 
1990; 343: 425-30. 
7 Staggers JE, Hernell O, Stafford RJ, Carey MC. Physical-chemical 
behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. 
Phase behavior and aggregation states of model lipid systems patterned after aqueous 
duodenal contents of healthy adult human beings. Biochemistry 1990; 29: 2028-40. 
8 Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of dietary 
and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and 
aggregation states of luminal lipids during duodenal fat digestion in healthy adult 
human beings. Biochemistry 1990; 29: 2041-56. 
9 Altmann SW, Davis HR, Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 
protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4. 
10 Jia L, Ma Y, Rong S, et al. Niemann-Pick C1-Like 1 deletion in mice 
prevents high-fat diet-induced fatty liver by reducing lipogenesis. Journal of lipid 
research 2010; 51: 3135-44. 
11 Davis HR, Jr., Hoos LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP, 
Altmann SW. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in 
ApoE-/- mice. Arteriosclerosis, thrombosis, and vascular biology 2007; 27: 841-9. 
12 Fielding CJ, Renston JP, Fielding PE. Metabolism of cholesterol-enriched 
chylomicrons. Catabolism of triglyceride by lipoprotein lipase of perfused heart and 
adipose tissues. Journal of lipid research 1978; 19: 705-11. 
13 Klein RL, Rudel LL. Cholesterol absorption and transport in thoracic duct 
lymph lipoproteins of nonhuman primates. Effect of dietary cholesterol level. Journal 
of lipid research 1983; 24: 343-56. 
14 Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly 
contributes to HDL biogenesis in vivo. The Journal of clinical investigation 2006; 116: 
1052-62. 
15 Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in 
sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 
1771-5. 
16 Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, 
Hobbs HH. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol 
   29 
secretion and reduces fractional absorption of dietary cholesterol. The Journal of 
clinical investigation 2002; 110: 671-80. 
17 Bashtovyy D, Jones MK, Anantharamaiah GM, Segrest JP. Sequence 
conservation of apolipoprotein A-I affords novel insights into HDL structure-function. 
Journal of lipid research 2011; 52: 435-50. 
18 Luo CC, Li WH, Moore MN, Chan L. Structure and evolution of the 
apolipoprotein multigene family. Journal of molecular biology 1986; 187: 325-40. 
19 Patsch W, Gotto AM, Jr. Apolipoproteins: pathophysiology and clinical 
implications. Methods in enzymology 1996; 263: 3-32. 
20 Glomset JA. The metabolic role of lecithin: cholesterol acyltransferase: 
perspectives from pathology. Advances in lipid research 1973; 11: 1-65. 
21 Rader DJ. Molecular regulation of HDL metabolism and function: 
implications for novel therapies. The Journal of clinical investigation 2006; 116: 3090-
100. 
22 Castellani LW, Lusis AJ. ApoA-II versus ApoA-I: two for one is not 
always a good deal. Arteriosclerosis, thrombosis, and vascular biology 2001; 21: 1870-
2. 
23 Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. 
Annual review of biochemistry 2003; 72: 137-74. 
24 Ishibashi S, Schwarz M, Frykman PK, Herz J, Russell DW. Disruption of 
cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid 
and vitamin supplementation. The Journal of biological chemistry 1996; 271: 18017-
23. 
25 Erickson SK, Lear SR, Deane S, et al. Hypercholesterolemia and changes 
in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. Journal of 
lipid research 2003; 44: 1001-9. 
26 Nakamoto K, Wang S, Jenison RD, Guo GL, Klaassen CD, Wan YJ, 
Zhong XB. Linkage disequilibrium blocks, haplotype structure, and htSNPs of human 
CYP7A1 gene. BMC genetics 2006; 7: 29. 
27 Wang J, Freeman DJ, Grundy SM, Levine DM, Guerra R, Cohen JC. 
Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density 
lipoprotein cholesterol concentrations. The Journal of clinical investigation 1998; 101: 
1283-91. 
28 del Castillo-Olivares A, Gil G. Differential effects of sterol regulatory 
binding proteins 1 and 2 on sterol 12 alpha-hydroxylase. SREBP-2 suppresses the sterol 
12 alpha-hydroxylase promoter. The Journal of biological chemistry 2002; 277: 6750-
7. 
29 Yang Y, Eggertsen G, Gafvels M, Andersson U, Einarsson C, Bjorkhem 
I, Chiang JY. Mechanisms of cholesterol and sterol regulatory element binding protein 
regulation of the sterol 12alpha-hydroxylase gene (CYP8B1). Biochemical and 
biophysical research communications 2004; 320: 1204-10. 
30 Li-Hawkins J, Gafvels M, Olin M, et al. Cholic acid mediates negative 
feedback regulation of bile acid synthesis in mice. The Journal of clinical investigation 
2002; 110: 1191-200. 
31 Slatis K, Gafvels M, Kannisto K, et al. Abolished synthesis of cholic acid 
reduces atherosclerotic development in apolipoprotein E knockout mice. Journal of 
lipid research 2010; 51: 3289-98. 
32 Wang J, Gafvels M, Rudling M, Murphy C, Bjorkhem I, Einarsson C, 
Eggertsen G. Critical role of cholic acid for development of hypercholesterolemia and 
gallstones in diabetic mice. Biochemical and biophysical research communications 
2006; 342: 1382-8. 
 30 
33 Wang J, Einarsson C, Murphy C, Parini P, Bjorkhem I, Gafvels M, 
Eggertsen G. Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in 
normal and cholic acid-depleted mice. Journal of lipid research 2006; 47: 421-30. 
34 Abrahamsson A, Gafvels M, Reihner E, Bjorkhem I, Einarsson C, 
Eggertsen G. Polymorphism in the coding part of the sterol 12alpha-hydroxylase gene 
does not explain the marked differences in the ratio of cholic acid and 
chenodeoxycholic acid in human bile. Scandinavian journal of clinical and laboratory 
investigation 2005; 65: 595-600. 
35 Becker M, Staab D, Leiss O, von Bergmann K. Biliary lipid composition 
in patients with cystic fibrosis. Journal of pediatric gastroenterology and nutrition 
1989; 8: 308-12. 
36 Rosen H, Reshef A, Maeda N, et al. Markedly reduced bile acid synthesis 
but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted 
sterol 27-hydroxylase gene. The Journal of biological chemistry 1998; 273: 14805-12. 
37 Bjorkhem I, Leitersdorf E. Sterol 27-hydroxylase deficiency: a rare cause 
of xanthomas in normocholesterolemic humans. Trends in endocrinology and 
metabolism: TEM 2000; 11: 180-3. 
38 Dawson PA, Lan T, Rao A. Bile acid transporters. Journal of lipid 
research 2009; 50: 2340-57. 
39 Hulzebos CV, Renfurm L, Bandsma RH, et al. Measurement of 
parameters of cholic acid kinetics in plasma using a microscale stable isotope dilution 
technique: application to rodents and humans. Journal of lipid research 2001; 42: 
1923-9. 
40 Hofmann AF, Molino G, Milanese M, Belforte G. Description and 
simulation of a physiological pharmacokinetic model for the metabolism and 
enterohepatic circulation of bile acids in man. Cholic acid in healthy man. The Journal 
of clinical investigation 1983; 71: 1003-22. 
41 Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing 
controls glucose homeostasis. Cell metabolism 2009; 10: 167-77. 
42 Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. 
Targeting bile-acid signalling for metabolic diseases. Nature reviews Drug discovery 
2008; 7: 678-93. 
43 Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile 
acid receptor TGR5--connecting nutrition and metabolism. Thyroid : official journal of 
the American Thyroid Association 2008; 18: 167-74. 
44 Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy 
expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 
484-9. 
45 Hagenbuch B, Dawson P. The sodium bile salt cotransport family 
SLC10. Pflugers Archiv : European journal of physiology 2004; 447: 566-70. 
46 Hata S, Wang P, Eftychiou N, et al. Substrate specificities of rat oatp1 
and ntcp: implications for hepatic organic anion uptake. American journal of 
physiology Gastrointestinal and liver physiology 2003; 285: G829-39. 
47 Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama 
Y. Vectorial transport of bile salts across MDCK cells expressing both rat Na+-
taurocholate cotransporting polypeptide and rat bile salt export pump. American 
journal of physiology Gastrointestinal and liver physiology 2005; 288: G159-67. 
48 Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama 
Y. Vectorial transport of unconjugated and conjugated bile salts by monolayers of 
LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and 
Bsep. American journal of physiology Gastrointestinal and liver physiology 2006; 290: 
G550-6. 
   31 
49 Shneider BL. Intestinal bile acid transport: biology, physiology, and 
pathophysiology. Journal of pediatric gastroenterology and nutrition 2001; 32: 407-17. 
50 Weinman SA, Carruth MW, Dawson PA. Bile acid uptake via the human 
apical sodium-bile acid cotransporter is electrogenic. The Journal of biological 
chemistry 1998; 273: 34691-5. 
51 Wang W, Seward DJ, Li L, Boyer JL, Ballatori N. Expression cloning of 
two genes that together mediate organic solute and steroid transport in the liver of a 
marine vertebrate. Proceedings of the National Academy of Sciences of the United 
States of America 2001; 98: 9431-6. 
52 Seward DJ, Koh AS, Boyer JL, Ballatori N. Functional complementation 
between a novel mammalian polygenic transport complex and an evolutionarily ancient 
organic solute transporter, OSTalpha-OSTbeta. The Journal of biological chemistry 
2003; 278: 27473-82. 
53 Jakobsson T, Venteclef N, Toresson G, et al. GPS2 is required for 
cholesterol efflux by triggering histone demethylation, LXR recruitment, and 
coregulator assembly at the ABCG1 locus. Molecular cell 2009; 34: 510-8. 
54 Venteclef N, Jakobsson T, Ehrlund A, et al. GPS2-dependent 
corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and 
LXRbeta in the hepatic acute phase response. Genes & development 2010; 24: 381-95. 
55 Giguere V. Orphan nuclear receptors: from gene to function. Endocrine 
reviews 1999; 20: 689-725. 
56 Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the 
crossroads of lipid metabolism and inflammation. Annual review of cell and 
developmental biology 2004; 20: 455-80. 
57 Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An 
oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 
1996; 383: 728-31. 
58 Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear 
receptor LXR by oxysterols defines a new hormone response pathway. The Journal of 
biological chemistry 1997; 272: 3137-40. 
59 Fu X, Menke JG, Chen Y, et al. 27-hydroxycholesterol is an endogenous 
ligand for liver X receptor in cholesterol-loaded cells. The Journal of biological 
chemistry 2001; 276: 38378-87. 
60 Prufer K, Boudreaux J. Nuclear localization of liver X receptor alpha and 
beta is differentially regulated. Journal of cellular biochemistry 2007; 100: 69-85. 
61 Fan X, Kim HJ, Bouton D, Warner M, Gustafsson JA. Expression of liver 
X receptor beta is essential for formation of superficial cortical layers and migration of 
later-born neurons. Proceedings of the National Academy of Sciences of the United 
States of America 2008; 105: 13445-50. 
62 Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the 
nuclear sterol-activated receptors LXR and FXR. Nature reviews Molecular cell 
biology 2012; 13: 213-24. 
63 Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol 
uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009; 325: 
100-4. 
64 Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. 
Genes & development 2000; 14: 2831-8. 
65 Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory 
element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and 
LXRbeta. Genes & development 2000; 14: 2819-30. 
 32 
66 Katz A, Udata C, Ott E, et al. Safety, pharmacokinetics, and 
pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in 
healthy participants. Journal of clinical pharmacology 2009; 49: 643-9. 
67 Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor 
that is activated by farnesol metabolites. Cell 1995; 81: 687-93. 
68 Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for 
an orphan nuclear receptor. Science 1999; 284: 1365-8. 
69 Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear 
receptor for bile acids. Science 1999; 284: 1362-5. 
70 Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the 
nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Molecular 
cell 2000; 6: 517-26. 
71 Brendel C, Schoonjans K, Botrugno OA, Treuter E, Auwerx J. The small 
heterodimer partner interacts with the liver X receptor alpha and represses its 
transcriptional activity. Mol Endocrinol 2002; 16: 2065-76. 
72 De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M. 
The negative effects of bile acids and tumor necrosis factor-alpha on the transcription 
of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-
4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear 
receptors. The Journal of biological chemistry 2001; 276: 30708-16. 
73 Yu XX, Watts LM, Manchem VP, Chakravarty K, Monia BP, McCaleb 
ML, Bhanot S. Peripheral reduction of FGFR4 with antisense oligonucleotides 
increases metabolic rate and lowers adiposity in diet-induced obese mice. PloS one 
2013; 8: e66923. 
74 Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid 
homeostasis by the farnesoid X receptor in liver and intestine. Journal of lipid research 
2007; 48: 2664-72. 
75 Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of 
membrane-type receptor for bile acids (M-BAR). Biochemical and biophysical 
research communications 2002; 298: 714-9. 
76 Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like 
peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. 
Biochemical and biophysical research communications 2005; 329: 386-90. 
77 Maruyama T, Tanaka K, Suzuki J, et al. Targeted disruption of G protein-
coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. The Journal of endocrinology 
2006; 191: 197-205. 
78 Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the 
development of atherosclerosis in mice. Proceedings of the National Academy of 
Sciences of the United States of America 2002; 99: 7604-9. 
79 Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, 
Kooistra T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion 
regression in apoE*3Leiden mice: time course and mechanisms. Journal of lipid 
research 2009; 50: 301-11. 
80 Schuster GU, Parini P, Wang L, et al. Accumulation of foam cells in liver 
X receptor-deficient mice. Circulation 2002; 106: 1147-53. 
81 Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta 
reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha 
and apoE. The Journal of clinical investigation 2007; 117: 2337-46. 
82 Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA. FXR 
deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arteriosclerosis, thrombosis, 
and vascular biology 2006; 26: 2316-21. 
   33 
83 Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, 
Brewer B, Jr., Gonzalez FJ. Effects of FXR in foam-cell formation and atherosclerosis 
development. Biochimica et biophysica acta 2006; 1761: 1401-9. 
84 Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional 
farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient 
mice. Journal of lipid research 2005; 46: 2595-604. 
85 Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. 
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- 
and apoE-/- mice. Journal of lipid research 2009; 50: 1090-100. 
86 Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect 
of farnesoid X receptor. American journal of physiology Heart and circulatory 
physiology 2009; 296: H272-81. 
87 Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of 
the farnesoid X receptor in the vasculature. Proceedings of the National Academy of 
Sciences of the United States of America 2004; 101: 3668-73. 
88 He F, Li J, Mu Y, et al. Downregulation of endothelin-1 by farnesoid X 
receptor in vascular endothelial cells. Circulation research 2006; 98: 192-9. 
89 Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for 
the treatment of dyslipidemia and cardiovascular disease. Journal of lipid research 
2012; 53: 1723-37. 
90 Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 
agonist isolated from Olea europaea. Biochemical and biophysical research 
communications 2007; 362: 793-8. 
91 Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for 
normal glucose homeostasis. The Journal of clinical investigation 2006; 116: 1102-9. 
92 Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor 
FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proceedings of the 
National Academy of Sciences of the United States of America 2006; 103: 1006-11. 
93 Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X 
receptor modulates adiposity and peripheral insulin sensitivity in mice. The Journal of 
biological chemistry 2006; 281: 11039-49. 
94 Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X 
receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding 
transition. The Journal of biological chemistry 2005; 280: 29971-9. 
95 Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate 
metabolism by the farnesoid X receptor. Endocrinology 2005; 146: 984-91. 
96 Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, 
Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer 
partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. The Journal of 
biological chemistry 2004; 279: 23158-65. 
97 Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second 
generation antisense oligonucleotides. Expert opinion on drug metabolism & toxicology 
2013; 9: 169-82. 
98 Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. 
Nature 1994; 372: 333-5. 
99 Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Muller M, 
Nicklin P. Second-generation antisense oligonucleotides: structure-activity 
relationships and the design of improved signal-transduction inhibitors. Biochemical 
Society transactions 1996; 24: 630-7. 
100 Manoharan M. 2'-carbohydrate modifications in antisense oligonucleotide 
therapy: importance of conformation, configuration and conjugation. Biochimica et 
biophysica acta 1999; 1489: 117-30. 
 34 
101 Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense 
oligonucleotides for the treatment of dyslipidaemia. European heart journal 2012; 33: 
1451-8. 
102 Hu X, Steffensen KR, Jiang ZY, Parini P, Gustafsson JA, Gafvels M, 
Eggertsen G. LXRbeta activation increases intestinal cholesterol absorption, leading to 
an atherogenic lipoprotein profile. Journal of internal medicine 2012; 272: 452-64. 
103 Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: 
cholesterol lowering and beyond. Expert review of cardiovascular therapy 2008; 6: 
447-70. 
104 Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal 
cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8. 
105 Brown WV. Cholesterol absorption inhibitors: defining new options in 
lipid management. Clinical cardiology 2003; 26: 259-64. 
106 Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe 
acts by blocking the sterol-induced internalization of NPC1L1. Cell metabolism 2008; 
7: 508-19. 
107 Xie C, Li N, Chen ZJ, Li BL, Song BL. The small GTPase Cdc42 
interacts with Niemann-Pick C1-like 1 (NPC1L1) and controls its movement from 
endocytic recycling compartment to plasma membrane in a cholesterol-dependent 
manner. The Journal of biological chemistry 2011; 286: 35933-42. 
108 Campana G, Pasini P, Roda A, Spampinato S. Regulation of ileal bile 
acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the 
farnesoid X receptor. Biochemical pharmacology 2005; 69: 1755-63. 
109 Zhang Y, Hong JY, Rockwell CE, Copple BL, Jaeschke H, Klaassen CD. 
Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver 
international : official journal of the International Association for the Study of the Liver 
2012; 32: 58-69. 
110 Miyata M, Takamatsu Y, Kuribayashi H, Yamazoe Y. Administration of 
ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal 
fibroblast growth factor 15 expression. The Journal of pharmacology and experimental 
therapeutics 2009; 331: 1079-85. 
111 Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW. Enzymatic 
reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. 
Cell metabolism 2007; 5: 73-9. 
112 Shafaati M, Olin M, Bavner A, et al. Enhanced production of 24S-
hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. 
Journal of internal medicine 2011; 270: 377-87. 
113 Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, 
Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the 
nuclear oxysterol receptor LXR alpha. Cell 1998; 93: 693-704. 
114 Alberti S, Schuster G, Parini P, et al. Hepatic cholesterol metabolism and 
resistance to dietary cholesterol in LXRbeta-deficient mice. The Journal of clinical 
investigation 2001; 107: 565-73. 
115 Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and 
ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-
9. 
116 Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf 
DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the 
liver X receptors alpha and beta. The Journal of biological chemistry 2002; 277: 
18793-800. 
117 Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, 
Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol 
   35 
receptor LXR alpha. Proceedings of the National Academy of Sciences of the United 
States of America 2000; 97: 12097-102. 
118 Quinet EM, Savio DA, Halpern AR, et al. Liver X receptor (LXR)-beta 
regulation in LXRalpha-deficient mice: implications for therapeutic targeting. 
Molecular pharmacology 2006; 70: 1340-9. 
119 Lund EG, Peterson LB, Adams AD, et al. Different roles of liver X 
receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual 
agonist in mice deficient in each subtype. Biochemical pharmacology 2006; 71: 453-
63. 
120 Hu X, Steffensen KR, Jiang ZY, Parini P, Gustafsson JA, Gafvels M, 
Eggertsen G. LXR beta activation increases intestinal cholesterol absorption, leading to 
an atherogenic lipoprotein profile. Journal of internal medicine 2012; 272: 452-64. 
121 Lo Sasso G, Murzilli S, Salvatore L, et al. Intestinal specific LXR 
activation stimulates reverse cholesterol transport and protects from atherosclerosis. 
Cell metabolism 2010; 12: 187-93. 
122 Ellis E, Axelson M, Abrahamsson A, et al. Feedback regulation of bile 
acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest 
inhibitor. Hepatology 2003; 38: 930-8. 
123 Howard WR, Pospisil JA, Njolito E, Noonan DJ. Catabolites of 
cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated 
nuclear receptor. Toxicology and applied pharmacology 2000; 163: 195-202. 
124 Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid 
metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring 
FXR antagonist. Cell metabolism 2013; 17: 225-35. 
125 Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is 
linked to marked but reversible alterations in the mouse distal gut microbiome. Cell 
host & microbe 2008; 3: 213-23. 
126 Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet 
determines the composition of the murine gut microbiome independently of obesity. 
Gastroenterology 2009; 137: 1716-24 e1-2. 
127 Cani PD, Neyrinck AM, Fava F, et al. Selective increases of 
bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through 
a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-83. 
128 Cani PD, Delzenne NM. The role of the gut microbiota in energy 
metabolism and metabolic disease. Current pharmaceutical design 2009; 15: 1546-58. 
129 Martinez I, Wallace G, Zhang C, et al. Diet-induced metabolic 
improvements in a hamster model of hypercholesterolemia are strongly linked to 
alterations of the gut microbiota. Applied and environmental microbiology 2009; 75: 
4175-84. 
130 Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in 
human adults with type 2 diabetes differs from non-diabetic adults. PloS one 2010; 5: 
e9085. 
131 Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace 
NR. Molecular-phylogenetic characterization of microbial community imbalances in 
human inflammatory bowel diseases. Proceedings of the National Academy of Sciences 
of the United States of America 2007; 104: 13780-5. 
132 Islam KB, Fukiya S, Hagio M, et al. Bile acid is a host factor that 
regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141: 
1773-81. 
133 Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera 
RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in 
 36 
hyperlipidemic mice without causing hepatic steatosis. Journal of lipid research 2005; 
46: 872-84. 
134 Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of 
apolipoprotein B and low-density lipoprotein cholesterol by short-term administration 
of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35. 
135 Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B 
synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. European heart 
journal 2011; 32: 2650-9. 
136 Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, 
Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin 
type 9 reduces serum LDL in hyperlipidemic mice. Journal of lipid research 2007; 48: 
763-7. 
137 Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic 
RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL 
cholesterol in nonhuman primates. Proceedings of the National Academy of Sciences of 
the United States of America 2008; 105: 11915-20. 
 
 
